Taysha Gene Therapies (TSHA) Gets a Buy from Cantor Fitzgerald

Cantor Fitzgerald analyst Kristen Kluska maintained a Buy rating on Taysha Gene Therapies (TSHA – Research Report) yesterday and set a price target of $7.00. The company’s shares closed yesterday at $2.57.

According to TipRanks, Kluska is a 5-star analyst with an average return of 27.5% and a 39.22% success rate. Kluska covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, ADMA Biologics, and Celldex.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Taysha Gene Therapies with a $7.17 average price target, a 178.99% upside from current levels. In a report released today, Needham also maintained a Buy rating on the stock with a $7.00 price target.

Based on Taysha Gene Therapies’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $3.61 million and a net profit of $47.74 million. In comparison, last year the company earned a revenue of $2.5 million and had a GAAP net loss of $55.08 million

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Taysha Gene Therapies (TSHA) Company Description:

Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. It is advancing a deep and sustainable product portfolio of 18 gene therapy product candidates, with exclusive options to acquire four additional development programs. Its product candidates include TSHA-101, TSHA-118, TSHA-102, TSHA-103, and TSHA-104.